# ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

> **NCT02021279** · NA · COMPLETED · sponsor: **Integra LifeSciences Corporation** · enrollment: 161 (actual)

## Conditions studied

- Pelvic Organ Prolapse

## Interventions

- **DEVICE:** MatriStem Pelvic Floor Matrix
- **PROCEDURE:** native tissue repair

## Key facts

- **NCT ID:** NCT02021279
- **Lead sponsor:** Integra LifeSciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-11
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021279, "ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02021279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*